XBIT

XBiotech Inc

XBIT, USA

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

https://www.xbiotech.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XBIT
stock
XBIT

Aug Big Picture: What is Planet Labs PBC Equity Warrants P E ratio telling us - Market Risk Report & High Accuracy Swing Trade Signals baoquankhu1.vn

Read more →
XBIT
stock
XBIT

Will XBIT stock attract ESG investors - Market Growth Review & Reliable Entry Point Trade Alerts bollywoodhelpline.com

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.46

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-3.60 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.48 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.03

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 14.68% of the total shares of XBiotech Inc

1.

Vanguard Group Inc

(3.1009%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.0009%)

since

2025/07/31

3.

Millennium Management LLC

(1.8084%)

since

2025/06/30

4.

BlackRock Inc

(1.2254%)

since

2025/06/30

5.

Geode Capital Management, LLC

(0.7238%)

since

2025/06/30

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6592%)

since

2025/07/31

7.

RBF LLC

(0.656%)

since

2025/06/30

8.

Goldman Sachs Group Inc

(0.3676%)

since

2025/06/30

9.

Fidelity Extended Market Index

(0.3493%)

since

2025/07/31

10.

Northern Trust Corp

(0.3055%)

since

2025/06/30

11.

Morgan Stanley - Brokerage Accounts

(0.2814%)

since

2025/06/30

12.

Dimensional Fund Advisors, Inc.

(0.2328%)

since

2025/06/30

13.

State Street Corp

(0.2248%)

since

2025/06/30

14.

EA Bridgeway Omni Small-Cap Value ETF

(0.1953%)

since

2025/08/29

15.

Bridgeway Capital Management, LLC

(0.1946%)

since

2025/06/30

16.

Empowered Funds, LLC

(0.1946%)

since

2025/06/30

17.

Bank of New York Mellon Corp

(0.1589%)

since

2025/06/30

18.

Connor Clark & Lunn Inv Mgmt Ltd

(0.1583%)

since

2025/06/30

19.

Y-Intercept (Hong Kong) Ltd

(0.1571%)

since

2025/06/30

20.

iShares Micro-Cap ETF

(0.1552%)

since

2025/08/31

21.

Squarepoint Ops LLC

(0.1305%)

since

2025/06/30

22.

Susquehanna International Group, LLP

(0.1292%)

since

2025/06/30

23.

Fidelity Total Market Index

(0.1161%)

since

2025/07/31

24.

Citadel Advisors Llc

(0.1065%)

since

2025/06/30

25.

Qube Research & Technologies

(0.1057%)

since

2025/06/30

26.

Extended Equity Market Fund K

(0.1028%)

since

2025/06/30

27.

Fidelity Series Total Market Index

(0.0872%)

since

2025/07/31

28.

Cubist Systematic Strategies, LLC

(0.085%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.077%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.077%)

since

2025/06/30

31.

Spartan Extended Market Index Pool F

(0.0752%)

since

2025/07/31

32.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0734%)

since

2025/03/31

33.

Fidelity Nasdaq Composite Index

(0.0556%)

since

2025/07/31

34.

DFA US Micro Cap I

(0.05%)

since

2025/07/31

35.

Goldman Sachs Absolute Ret Trckr Instl

(0.0495%)

since

2025/06/30

36.

NT Ext Equity Mkt Idx Fd - NL

(0.0447%)

since

2025/06/30

37.

PPF Helix Biotechnology I USD

(0.0443%)

since

2025/05/31

38.

Avantis US Small Cap Equity ETF

(0.0434%)

since

2025/08/30

39.

Spartan Total Market Index Pool G

(0.0394%)

since

2025/07/31

40.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0355%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0

Latest Release

Date

2025-09-30

EPS Actual

-0.2

EPS Estimate

0

EPS Difference

-0.2

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(7)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.